
Learn how low libido differs from erectile dysfunction, why testosterone is only one factor, and what a broad clinical assessment includes.

Low libido concerns sexual interest while erectile dysfunction concerns persistent erection difficulties, and separating these symptoms helps clinicians assess testosterone alongside other possible medical causes.
This article is for informational purposes only and is not medical advice. A qualified healthcare professional should assess persistent symptoms and make individual testing or treatment decisions.
Libido is the interest or motivation to take part in sexual activity. It describes wanting sex rather than the physical ability to achieve an erection. A change in desire is therefore a different symptom from a change in erection quality.
The European Association of Urology (EAU) recommends asking about distinct parts of sexual function. These include desire and arousal as well as erections. Ejaculation and orgasm also belong in the history rather than being folded into a single question about sexual performance.
This separation matters because a man can have less interest in sex while still being able to get an erection. Another man may want sexual activity but have difficulty getting or keeping an erection. Both concerns deserve attention without assuming they have the same explanation.
Keeping the domains separate also makes a combined concern easier to describe. If both interest and erection ability have changed, both belong in the account. A single phrase such as “sexual performance problems” can leave the clinician needing to establish which function is actually affected.
A useful description of low libido focuses on the change in interest itself. Has sexual motivation decreased? Is the concern about wanting sex rather than about what happens physically during sexual activity?
Those questions help keep the symptom clear. They do not require the reader to decide on a cause before speaking with a clinician. Testostra's guide to describing reduced sexual interest offers further context on assessment.
Erectile function is the ability to attain and maintain an erection sufficient for satisfactory sexual activity. The EAU defines ED as a persistent inability to do so. An occasional difficulty by itself does not meet that definition.
Unlike libido, erection ability concerns a physical response rather than motivation alone. But that does not make ED a purely physical condition. The EAU describes organic and psychological causes that often overlap.
Vascular and metabolic factors include cardiovascular disease and high blood pressure. Diabetes and abnormal blood lipids are also relevant, along with obesity and metabolic syndrome. Smoking and limited physical activity appear among the factors listed in the guideline.
This is why a discussion about erections can become a discussion about general health. The question is not simply whether sexual interest remains present. Clinicians also consider conditions that may affect erectile function despite preserved desire.
Neurologic contributors include conditions affecting the brain or spinal cord. The EAU also lists stroke and diabetes-related nerve problems. Pelvic or urethral surgery and radiotherapy can be relevant to the history.
Anatomical factors are another pathway in the guideline. A history of pelvic treatment or injury therefore belongs in the conversation rather than being set aside as unrelated to a hormone concern.
Some blood-pressure medicines and some antidepressants may contribute to ED. The EAU also lists antipsychotics and antiandrogens alongside recreational substances. A medication review is part of investigating possible causes, not a reason to stop or change prescribed treatment without medical advice.
The clinical task is to review these exposures alongside the symptom history. Seeing a medicine on a list does not establish that it caused an individual's erection difficulty. A broader account of ED causes helps place medication effects among the other possibilities.
Anxiety and depression can contribute to erection difficulties. Distress and performance-related concerns also matter, as do relationship difficulties. The guideline notes that psychological distress commonly occurs alongside ED.
These are clinical assessment topics rather than reasons to dismiss symptoms as “just psychological.” They also need not compete with vascular or hormonal explanations. More than one pathway may be present in the same person.
Hormonal contributors include hypogonadism and some thyroid or other endocrine disorders. Their place on this list is important: hormones are relevant without being the default explanation for every erection change.
The interaction between desire and erections becomes especially important when testosterone is being considered. Low testosterone can be relevant to sexual symptoms, but the EAU says those symptoms are not exclusive to hypogonadism. Clinicians interpret them within the person's wider medical and laboratory context.
For late-onset hypogonadism, the guideline requires compatible symptoms and signs together with consistently low morning testosterone on at least two occasions. It recommends morning fasting measurement and confirmation of a low result before treatment. Symptoms and test results are therefore considered together rather than used as substitutes for each other.
That distinction is central to understanding an initial testosterone test. A report of low desire is not a testosterone result. Equally, an isolated low measurement does not replace the clinical assessment.
The EAU recommends a comprehensive medical and sexual history for men presenting with ED. A focused physical examination and relevant laboratory testing are also part of assessment.
The history helps distinguish the following questions:
Morning erections are one part of that history rather than the whole assessment. A change in them belongs alongside questions about desire and erections during sexual activity. It does not remove the need for a medical history and the other elements of the guideline's recommended evaluation.
The guideline also recommends asking about other sexual-function domains. These details help clinicians weigh the concern as a whole rather than label every sexual change as a testosterone symptom.
The EAU recommends assessing relevant cardiovascular and metabolic factors. This includes blood pressure and blood glucose or HbA1c. Blood lipids also matter when these checks have not been done recently.
Likewise, discussing glucose and lipids does not mean the clinician has dismissed the sexual concern. It reflects the guideline's approach to ED as a symptom that merits attention to wider health. The sexual history and general medical assessment inform each other.
ED is associated with cardiovascular disease. That association does not prove that heart disease caused an individual's symptoms, but it supports discussing cardiovascular risk with a clinician.
For someone with persistent erection difficulties, the useful next conversation is therefore broader than “Is my testosterone low?” It includes the erection pattern and the person's medical history. Medication exposure and psychological or relationship factors belong in that discussion too.
The treatment evidence reinforces the distinction between wanting sex and being able to maintain an erection. Testosterone therapy may improve aspects of sexual function in men with confirmed hypogonadism. The EAU reports that the benefit varies with baseline testosterone and other health conditions.
In the EAU's summary of TRAVERSE, testosterone gel improved sexual activity and desire over two years. It did not improve erectile function. The studied population was middle-aged and older men with hypogonadism and existing or increased cardiovascular risk.
This finding concerns the studied population, not every man with ED.
These are different treatment outcomes. More sexual activity or greater interest does not measure the same function as getting and keeping an erection. When a clinician discusses expected benefits, it matters which outcome the evidence actually examined and which symptom is troubling the patient.
The EAU also reports that testosterone therapy alone was clinically effective for ED only in men with milder ED in the evidence it reviewed. It states that there is no evidence for using testosterone therapy to treat sexual dysfunction in eugonadal men, meaning men whose testosterone is in the normal range.
The practical implication is not to choose a hormone treatment from the symptom label. Clinicians first establish whether hypogonadism is present and assess the other possible contributors to ED. A plan directed at confirmed hormone deficiency addresses a different question from a plan for erection difficulties with another cause.
For the reader, clear symptom language makes that distinction easier to discuss. Reporting whether the main change is desire or erection ability gives the clinician a more precise starting point. Reporting both when both have changed preserves the full picture.
Sexual desire and erectile function should be assessed separately but interpreted together within a person's hormonal and wider health context.
Choosing an assessment for reduced desire or persistent erection difficulties is a clinical decision; Testostra adds educational context for the hormone questions that follow. Its evidence-led coverage helps men understand uncertainty about possible testosterone-related symptoms and discuss potential causes without mistaking an article for a diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra